We report three cases of severe haemorrhagic rupture of luteal ovarian cyst requiring surgical haemostasis in young women treated with long-term oral anticoagulation for antiphospholipid syndrome (APS) who used no contraception. At the time of bleeding, the international normalized ratios were 3.78, 4.24, and 7.11. Anticoagulation was resumed post-operatively, in association with antigonadotropic progestins to induce ovulatory suppression. A systematic use of these progestins should probably be discussed in young women receiving long-term warfarin for APS. Ovarian haemorrhage must be considered when such patients develop acute abdominal pain.
Rosove MH , Brewer PM . Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients . Ann Intern Med1992; 117: 303–308 .
2.
Derksen RHWM , DeGroot PG , Kater L , Nieuwenhuis HK . Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment . Ann Rheum Dis1993; 52: 689–692 .
3.
Khamashta MA , Cuadrado MJ , Mujic F et al, The management of thrombosis in the antiphospholipid-antibody syndrome . N Engl J Med1995; 332: 993–997 .
4.
Krnic-Barrie S , O'Connor CR , Looney SW et al. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis . Arch Intern Med1997; 157: 2101–2108 .
5.
Piette JC , Cacoub P . Antiphospholipid syndrome in the elderly: caution . Circulation1998; 97: 2195–2196 .
6.
Levine MN , Raskob G , Landefeld S , Kearon C . Hemorrhagic complications of anticoagulant treatment . Chest1998; 114: 511S–523S .
7.
Boffa MC , Piette JC . Questions-answers about antiphospholipid-protein antibodies and the ‘antiphospholipid antibody syndrome’ . Ann Med Interne1996; 147(Suppl 1): 54–56 .
8.
Landefeld CS , Beyth RJ . Anticoagulant-related bleeding; clinical epidemiology, prediction, and prevention . Am J Med1993; 95: 315–328 .
9.
Fihn SD , McDonell M , Martin D , et al. Risk factors for complications of chronic anticoagulation. A multicenter study . Ann Intern Med1993; 118: 511–520 .
10.
Palareti G , Leali N , Coccheri S , et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) . Lancet1996; 348: 423–428 .
11.
The Stroke Prevention in Atrial Fibrillation Investigators . Bleeding during antithrombotic therapy in patients with atrial fibrillation . Arch Intern Med1996; 156: 409–416 .
12.
Beyth RJ , Quinn LM , Landefeld CS . Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin . Am J Med1998; 105: 91–99 .
13.
Al-Sayegh FA , Ensworth S , Huang S et al. Hemorrhagic complications of longterm anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome . J Rheumatol1997; 24: 1716–1718 .
14.
Sopher IM , Ming SC . Fatal corpus luteum hemorrhage during anticoagulant therapy . Obstet Gynecol1971; 37: 695–697 .
15.
Matseoane S , Batts JA Jr , Mandeville EO . Ovarian hemorrhage complicating warfarin sodium anticoagulant therapy . Am J Obstet Gynecol1976; 124: 766–767 .
16.
Semchyshyn S , Zuspan FP . Ovarian hemorrhage due to anticoagulants . Am J Obstet Gynecol1978; 131: 837–844 .
17.
Peters WA III , Thiagarajah S , Thornton WN Jr . Ovarian hemorrhage in patients receiving anticoagulant therapy . J Reprod Med1979; 22: 82–86 .
18.
Hallat JG , Steele CH , Snyder M . Ruptured corpus luteum with hemoperitoneum: a study of 173 surgical cases . Am J Obstet Gynecol1984; 149: 5–9 .
19.
Hill JA , Kassam SH . Ovarian hemorrhage in ovulating women receiving anticoagulant therapy. A report of two cases . J Reprod Med1984; 29: 205–208 .
20.
Asherson RA . Adrenal, hepatic, and other intraabdominal manifestations in the antiphospholipid syndrome. In: The Antiphospholipid Syndrome, Asherson RA , Cervera R , Piette JC , Shoenfeld Y (ed). Boca Raton: CRC Press1996, 183–193.
21.
Hibbard LT . Corpus luteum surgery . Am J Obstet Gynecol1979; 135: 666–670 .
22.
Ruffatti A , Aversa S , Del Ross T et al. Antiphospholipid antibody syndrome associated with ovarian cancer. A new paraneoplastic syndrome?J Rheumatol1994; 21: 2162–2163 .
23.
Piette JC , Wechsler B . Other aspects of the management of the antiphospholipid syndrome. In: The Antiphospholipid Syndrome, Asherson RA , Cervera R , Piette JC , Shoenfeld Y (Ed). Boca Raton: CRC Press . 1996, 309–314.
24.
Petri M , Clinical and management aspects of the antiphospholipid syndrome. In: Dubois' Lupus Erythematosus, 5th edition, Wallace DJ , Hahn BH (ed). Baltimore: Williams & Wilkins , 1997, 1067–1096.
25.
Chabbert-Buffet N , Blétry O , Clauvel JP et al. Pregnane progestin is a safe contraception in systemic lupus erythematosus (abstract) . Lupus1998; 7 (Suppl 1): 111-111 .
26.
Boumpas DT , Austin HA III , Vaughan EM et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy . Ann Intern Med1993; 119: 366–369 .
27.
Gompel A , Blétry O . Contraception et grossesse au cours du lupus érythémateux systémique . Rev Prat1990; 40: 1946–1951 .
28.
Tayob Y , Adams J , Jacobs HS , Guillebaud J . Ultrasound demonstration of increased frequency of functional cysts in women using progestogen-only oral contraception . Br J Obstet Gynaecol1985; 92: 1003–1009 .
29.
Moll S , Ortel TL . Monitoring warfarin therapy in patients with lupus anticoagulants . Ann Intern Med1997; 127: 177–185 .
30.
Praprotnik S , Prezely J . Ovaries in systemic lupus erythematosus . Lupus1995; 4: 418-418 .
